Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2006.12.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study.
Therap Adv Gastroenterol
November 2024
First Department of Medicine, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Ulmenweg 18, Erlangen 91054, Germany.
Background: Data regarding multiple switches including reverse switching between infliximab and its biosimilars are scarce in the field of inflammatory bowel diseases (IBD).
Objectives: We investigated the clinical effectiveness as primary outcome measure after repeated switches. Secondary endpoints included C-reactive protein (CRP) levels, immunogenicity (trough levels (TL); anti-drug antibodies (ADA), safety and drug persistence.
Multidisciplinary management of ulcerative colitis complicated by immune checkpoint inhibitor-associated colitis with life-threatening gastrointestinal hemorrhage: A case report.
World J Gastrointest Surg
July 2024
Department of Gastroenterology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui Province, China.
Background: Programmed cell death 1 (PD-1) inhibitors are immune checkpoint inhibitors (ICI) that have demonstrated significant efficacy in treating various advanced malignant tumors. While most patients tolerate treatment well, several adverse drug reactions, such as fatigue, myelosuppression, and ICI-associated colitis, have been reported.
Case Summary: This case involved a 57-year-old male patient with ulcerative colitis complicated by hepatocarcinoma who underwent treatment with tirelizumab (a PD-1 inhibitor) for six months.
We present the case of a 52-year-old woman diagnosed with stage IV clear cell renal cell carcinoma who received combination of surgery and systemic therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4). During treatment, patient presented oral intolerance, vomiting and abdominal pain. Computed tomography (CT) and gastroscopy (EGD) were performed, identifying findings suggestive of severe gastro-duodenitis with friability and diffuse oedema of the mucosa and deep ulcers.
View Article and Find Full Text PDFSurgical management of intramedullary cervical spinal sarcoidosis complicated by transient unilateral weakness: A case report.
Surg Neurol Int
March 2024
Department of Orthopedic Surgery, Boston Medical Center, One Boston Medical Center Place, Boston, Massachusetts, United States.
Background: Sarcoidosis, a multisystem inflammatory non-caseating granulomatous disease, can present with neurologic lesions in up to 10% of patients.
Case Description: A 57-year-old male presented with three months of worsening upper extremity radicular pain associated with dysmetria, hyperreflexia, bilateral Hoffman's, and positive Babinski signs. The contrast magnetic resonance imaging (MRI) showed a diffuse T2 signal hyperintensity and T1-enhancing 2.
Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument.
Pract Lab Med
March 2024
DIESSE Diagnostica Senese S.p.A. Società Benefit: Strada dei Laghi 35-39, Monteriggioni, Siena, Italy.
Article Synopsis
- The study aimed to automate immunoassays for measuring serum levels of infliximab and adalimumab along with anti-drug antibodies using the CHORUS Promonitor kits.
- By comparing the automated kits against the manual versions, researchers analyzed sensitivity and specificity while running tests using human serum samples and drug additions on the CHORUS TRIO instrument.
- Results showed that the automated kits were highly accurate and consistent, demonstrating strong agreement with manual kits and confirming their potential for use in clinical settings for monitoring patients treated with these drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!